Passive immunotherapy as a vaccine against hepatitis C
This article has no abstract so we have provided the first paragraph of the full text.
The diversity of HCV makes immunotherapy or vaccine design very difficult. Law et al. have identified broadly neutralizing antibodies from a human with hepatitis C and demonstrated their HCV-targeting activity in mice with a chimeric human–mouse liver.
Full text of this article is available with one of the following:
- Membership of the American College of Gastroenterology. If already a member, please login.
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
